Compare Newmont Corporation (NEM) vs Revvity Inc (RVTY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Newmont Corporation vs Revvity Inc — how do they compare? Newmont Corporation trades at $117.84 (market cap $121.75B), while Revvity Inc trades at $154.18 (market cap $16.98B). The key difference: Newmont Corporation is far larger — about 7.2× Revvity Inc's market cap, and Newmont Corporation pays the higher dividend (0.9%). Which is the better fit depends on your goals — on Pluang, investors hold Newmont Corporation for 58 Days and Revvity Inc for 12 Days on average.
| NEM | RVTY | |
|---|---|---|
Market Cap | $121.75B | $16.98B |
Volume | 5,421,125 | 1,456,900 |
Sector | Basic Materials | Health |
52-Week High | $135.14 | $157.36 |
52-Week Low | $78.63 | $82.26 |
Typical Hold Time | 58 Days | 12 Days |
Enterprise Value | $118.34B | $19.30B |
Dividend Yield | 0.9% | 0.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Newmont Corporation (NEM) trades at $115.55, up 1.77% today, with a bearish technical signal despite strong fundamentals. The company reported record free cash flow of $5.3 billion in H1 2026 and has beaten earnings estimates for three consecutive quarters. Revenue grew to $22.67 billion in 2025, with net income margin expanding to 33.36%.
Outlook remains positive with a consensus price target of $136.83, implying 18% upside, supported by operational improvements and favorable gold prices. Risks include gold price volatility and execution of growth projects. Analyst sentiment is strongly bullish with 76% buy ratings and no sell recommendations.
RVTY trades at $152.16, down 0.94% on the day, but maintains a bullish technical trend with strong moving average signals and support near $149. The company has consistently beaten earnings estimates in recent quarters, with Q3 2026 results expected soon. Revenue remains stable around $2.9 billion, though net income margins have softened slightly. Recent news highlights product launches and strategic acquisitions, such as the Human Cell Design deal, to bolster its life sciences portfolio.
The outlook is supported by analyst optimism with a 51.72% buy rating and a consensus price target of $132.13, though the current price trades above this target. Key risks include premium valuation metrics, margin pressures, and exposure to macroeconomic headwinds. The stock's proximity to its 52-week high suggests momentum but warrants caution given rich multiples.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Newmont Corporation
Newmont Corp is primarily a gold producer with operations and/or assets in the United States, Canada, Mexico, Dominican Republic, Peru, Suriname, Argentina, Chile, Australia, and Ghana. It is also engaged in the production of copper, silver, lead and zinc. The company's operations are organized in five geographic regions: North America, South America, Australia, Africa and Nevada.
Read more on NEM →About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →
